Abstract
A 66-year-old man was diagnosed with metastatic prostate cancer to the bones. The patient started 223Ra-dichloride (Xofigo) therapy in April 2019. 99mTc-MDP bone scan and 18F-fluciclovine (Axumin) PET/CT showed discordant but overall complementary findings that indicated disease progression after 5 doses of Xofigo therapy. The patient's prostate-specific antigen increased from 33.81 ng/mL at baseline before Xofigo therapy and up to 394.3 ng/mL after the fifth dose of Xofigo treatment. Because of disease progression, Xofigo therapy was discontinued.
Original language | English (US) |
---|---|
Pages (from-to) | e486-e488 |
Journal | Clinical nuclear medicine |
Volume | 45 |
Issue number | 11 |
DOIs | |
State | Published - Nov 1 2020 |
Keywords
- F-fluciclovine PET/CT
- Ra-dichloride
- Tc-MDP
- bone scan
- prostate cancer
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging